Anti JAKS

Anti-JAKs safe in skin conditions

Shingrix works in at-risk JAKi patients, so why can’t they get it?

JAKis don’t beat TNFis in high-risk patients

Dual JAK1/TYK2 inhibitor outperforms tofacitinib

CV and cancer risks with JAKi: EULAR perspectives

Black box warning but no smoking gun for class effect yet

ORAL Surveillance risk groups narrow again

More real-world reassurance for JAKi and cancer
